期刊文献+

老年冠心病患者二级预防中降脂药物应用现状调查 被引量:2

Survey on the secondary prevention of coronary artery disease with statins in elderly patients
原文传递
导出
摘要 目的了解老年冠心病患者二级预防中降脂药物应用现状。方法2009年6月1日至2009年12月1日对我院门诊部老年冠心病患者进行用药调查,并进行统计分析。结果调查中资料完整的323例老年冠心病患者中他汀类(包括血脂康)药物使用率62.2%(201/323);统计显示三个不同年龄(60~69岁、70~79岁、80岁-)组间降脂药物使用率(44.8%、61.3%、71.3%)差异有统计学意义(x^2=18.477、P=0.00),并随年龄增长药物使用率有增高的趋势;另外,男性降脂药物使用率明显高于女性(分别为67.9%、37.7%,X^2=19.243、P=0.000)。结论老年冠心病患者二级预防用药中,降脂药物应用情况较冠心病用药指南要求尚有明显差距;亟待冠心病二级预防用药规范化。 Objective To probe into the usage of statins in the patients with coronary artery disease in elderly patients . Methods From Jun 1,2009 to Mar 31,2009 in our hospital, 323 elderly outpatients with coronary arte~ disease were included in the investigation. The data were statistically analyzed. Results 62. 2% of the patients used statins. The statins usage rates (44. 8% ,61.3% ,71.3% ) among three age groups(60 -69 years old,70- 79 years old, and 〉 80 years old)were significantly different. The rates of statins usage were significantly different between male and female groups. Conclusion The usage of statins as secondary prevention of coronary artery disease varies and there is urgent need to standardize the usage of statins according to the treatment guideline.
出处 《中国综合临床》 2011年第8期805-807,共3页 Clinical Medicine of China
关键词 冠心病 他汀类药物 二级预防 Coronary artery disease Statins Secondary prevention
  • 相关文献

参考文献15

  • 1Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services [ J ]. J Cardiopulm Rehabil Prey,2007,27 ( 5 ) :260-290.
  • 2Smith SC Jr, Alien J, Blair SN, et al. AHA./ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute [ J ]. Circulation, 2006, 113(19) :2363-2372.
  • 3Ridker PM, Danlelson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein [J]. N Engl J Med,2008,359(21 ) :2195-2207.
  • 4李瑜,张向阳.他汀类药物的多效性在心血管疾病中的应用进展[J].心血管病学进展,2010,31(1):127-130. 被引量:17
  • 5The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease [J]. JAMA, 1984,251 (3) :351-364.
  • 6Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S) [J]. Lancet,1994,344(8934) :1383-1389.
  • 7Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators [ J]. N Engl J Med, 1996,335 (14) :1001-1009.
  • 8Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [J]. N Engl J Med, 1998,339 (19) : 1349-1357.
  • 9Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [J]. Lancet,2002,360(9326) :7-22.
  • 10Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [ J ]. N Engl J Med ,2004,350 ( 15 ) : 1495-1504.

二级参考文献39

  • 1李盛姿,李平途.辛伐他汀与脂必妥治疗血脂异常的疗效比较(附78例分析)[J].福建医药杂志,2006,28(2):139-141. 被引量:3
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5223
  • 3American Heart Association.Heart Disease and stroke statistics-2009 update[R].Dallas Tex:American Heart Association,2009.
  • 4Schachter M.Chemical,pharmacokinetic and pharmacodynamic properties of statin:an update[J].Fundam Clin Pharmacol,2004,19:117-125.
  • 5Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].N Engl J Med,2008,359:2195-2207.
  • 6The Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S)[J].Lancet,1994,344:1383-1389.
  • 7Sacks FM,Pfeffer MA,Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level[J].N Engl J Med,1996,335:1001-1009.
  • 8The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID) study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level[J].N Engl J Med,1998,339:1349-1357.
  • 9Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals:a randomized placebo-controlled trial[J].Lancet,2002,360:7-22.
  • 10Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.the MIRACL Study,a randomized controlled trial[J].JAMA,2001,285:1711-1718.

共引文献54

同被引文献17

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部